In this article
Several Novo Nordisk
board members will step down from their positions after clashing with the controlling shareholder on the make-up of the firm.
The Danish pharma giant, known for its weight loss and diabetes drugs, said Tuesday that board directors and the Novo Nordisk Foundation — the firm’s controlling shareholder — had failed to reach an agreement on the future composition of the board.
“The Board proposed a renewal focusing on addition of select, new competencies while also maintaining continuity, whereas the Board of the Foundation wanted a more extensive reconfiguration,” said Helge Lund, chair of the board of directors.
